6876 Stock Overview
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
LAUNXP Biomedical Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$25.60 |
52 Week High | NT$30.35 |
52 Week Low | NT$20.55 |
Beta | 0 |
1 Month Change | -2.29% |
3 Month Change | -14.67% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 14.29% |
Recent News & Updates
Recent updates
Shareholder Returns
6876 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | -1.5% | -0.3% | 1.1% |
1Y | n/a | 2.2% | 28.2% |
Return vs Industry: Insufficient data to determine how 6876 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6876 performed against the TW Market.
Price Volatility
6876 volatility | |
---|---|
6876 Average Weekly Movement | 6.9% |
Pharmaceuticals Industry Average Movement | 3.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in TW Market | 8.8% |
10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6876 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6876's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | n/a | www.launxp.com |
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
LAUNXP Biomedical Co., Ltd Fundamentals Summary
6876 fundamental statistics | |
---|---|
Market cap | NT$824.03m |
Earnings (TTM) | NT$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6876 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6876 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$0 |
Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 6876 perform over the long term?
See historical performance and comparison